Drug & intervention

formoterol

RxCUI 25255

Clinical trials43
Recruiting0
Related conditions13
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Formoterol

Formoterol, also known as eformoterol, is a long-acting β2 agonist (LABA) used as a bronchodilator in the management of asthma and chronic obstructive pulmonary disease (COPD). Formoterol has an extended duration of action (up to 12 h) compared to short-acting β2 agonists such as salbutamol (albuterol), which are effective for 4 h to 6 h. Formoterol has a relatively rapid onset of action compared to other LABAs, and is effective within 2-3 minutes. The 2022 Global Initiative for Asthma report recommends a combination formoterol/inhaled corticosteroid inhaler as both a preventer and reliever treatment for asthma in adults. In children, a short-acting β2 adrenergic agonist (e.g., salbutamol) is still recommended. It was patented in 1972 and came into medical use in 1998. It is available as a generic medication. It is also marketed in the combination formulations budesonide/formoterol and mometasone/formoterol.

Read on Wikipedia ↗ Wikidata Q637247 ↗
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPDNCT03573817 · 2018-05-31
COMPLETED
Efficiency of Twice Daily Formoterol Versus Once Daily Tiotropium in Patients With GOLD A/B COPDNCT03258749 · 2017-11-01
UNKNOWN
A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal BlockNCT04494321 · 2017-06-19
COMPLETED
Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination TreatmentNCT02988869 · 2016-08-01
COMPLETED
A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal BlockNCT02850484 · 2016-03-01
COMPLETED
Small Airways Evaluation and TreatmentNCT02526758 · 2015-04-01
UNKNOWN
COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder InhalersNCT02291016 · 2015-02-01
COMPLETED
A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy VolunteersNCT02403713 · 2014-08-01
COMPLETED
Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated AsthmaNCT01912872 · 2013-11-11
TERMINATED
A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPDNCT01946620 · 2013-10-01
COMPLETED
Effects of Particle Size in Small Airways DysfunctionNCT01892787 · 2013-07-01
COMPLETED
The Effects of Atorvastatin Treatment in COPD PatientsNCT01748279 · 2012-12-01
COMPLETED
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT01574651 · 2012-05-01
COMPLETED
Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT01551888 · 2012-01-01
COMPLETED
Efficacy of Indacaterol 150 µg Versus FormoterolNCT01377428 · 2011-09-01
WITHDRAWN
Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy VolunteersNCT01398111 · 2011-05-01
COMPLETED
Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)NCT01290874 · 2011-03-30
COMPLETED
Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.NCT01194479 · 2010-08-01
COMPLETED
Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®NCT01048333 · 2010-01-01
COMPLETED
Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) PatientsNCT00929708 · 2009-06-01
COMPLETED
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease INCT00793624 · 2009-02-01
COMPLETED
Rapid Onset Action of Salbutamol Versus FormoterolNCT00900874 · 2009-01-01
UNKNOWN
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease IINCT00796653 · 2009-01-01
COMPLETED
Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199NCT00736489 · 2008-08-01
COMPLETED
The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic VariationsNCT00706446 · 2008-06-01
TERMINATED
Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)NCT00662779 · 2008-04-01
WITHDRAWN
Dose-response of Inhaled Formoterol Using Methacholine Challenge as a BioassayNCT00643578 · 2008-03-01
COMPLETED
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00557466 · 2007-10-01
COMPLETED
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent AsthmaNCT00545272 · 2007-10-01
COMPLETED
Change of Inspiratory Peak Flow in COPDNCT00561886 · 2007-04-01
COMPLETED
Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)NCT00443482 · 2007-02-01
COMPLETED
Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active ControlNCT00393458 · 2006-10-01
COMPLETED
Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) PatientsNCT00972140 · 2005-08-01
COMPLETED
Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in AsthmaNCT01786616 · 2005-01-01
COMPLETED
SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild AsthmaNCT00288379 · 2004-10-01
COMPLETED
Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary DiseaseNCT00134979 · 2004-10-01
COMPLETED
Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)NCT00742248 · 2004-09-01
COMPLETED
SHARE - Symbicort and Health Economics in a Real Life EvaluationNCT00259766 · 2004-04-01
COMPLETED
Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis TurbuhalerNCT00658255 · 2002-10-01
COMPLETED
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5NCT00651651 · 2002-08-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.